Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that BRCA1 oncogenic variants status confers therapeutic sensitivity to Bevacizumab, Olaparib in patients with High-Grade Serous Fallopian Tube Cancer.
This statement is based on a regulatory approval from the Health Canada:
LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.